Taxotere and Jevtana are the two most common chemotherapies used in prostate cancer. (They are both "taxane-based."). In this video, medical oncologist Mark Scholz, MD, discusses these two chemotherapies with emphasis on how the two are used in the advanced prostate cancer setting. (See our other videos on chemotherapy for more information about the use of chemotherapy in non-advanced settings.) He discusses how the side effects of these chemotherapies compare to those used in other cancers (lung cancer, for example), he discusses the differences between Taxotere and Jevtana, and the possibility of intermittent chemotherapy or adding other forms of chemotherapy if there is only a partial response to treatment.
0:07 How is PSA used to monitor the effectiveness of chemotherapy? Is chemotherapy for prostate cancer as intense as the chemotherapies used for other types of cancers?
3:37 How do you compare the two most common chemotherapy agents used in prostate cancer, Jevtana and Taxotere? How are they the same, and how are they different?
4:28 What are the other side effects of Jevtana and Taxotere? (fatigue and neuropathy are discussed in the question above.)
5:47 How does the use of ice help prevent hair loss, fingernail damage, etc.?
7:25 Are side effect mitigation techniques common in community hospital setting?
7:53 What kind of PSA response do you expect during and after chemotherapy?
9:18 Does a patient's PSA level at the initiation of chemotherapy determine how effective it will be, or does it affect the PSA response a doctor would expect if it was effective?
10:18 In what time frame do you expect a patient's PSA to nadir (reach its lowest point) during or after chemotherapy? What percentage of patients respond well to chemotherapy?
11:51 If a patient only has a partial response to chemotherapy, should their doctor consider adding other treatments?
13:46 What does it mean if a person has a stable PSA while on chemotherapy?
15:21 Where, in a patient's timeline, would you recommend PSMA PET scans?
16:13 If a patient's PSA is high, but stable after chemotherapy, could changing the type of chemotherapy potentially lower a patient's PSA?
18:12 How should patients speak with their doctors and medical professionals about any chemotherapy-related questions or concerns?
--
Don’t know your stage? Take the quiz: Visit www.prostatecancerstaging.org
To learn more about prostate cancer visit www.pcri.org
Sign up for our newsletter here to receive the latest updates on prostate cancer and the PCRI: pcri.org/join
Who we are:
The Prostate Cancer Research Institute (PCRI) is a 501(c)(3) not-for-profit organization that is dedicated to helping you research your treatment options. We understand that you have many questions, and we can help you find the answers that are specific to your case. All of our resources are designed by a multidisciplinary team of advocates and expert physicians, for patients. We believe that by educating yourself about the disease, you will have more productive interactions with your medical professionals and receive better-individualized care. Feel free to explore our website at pcri.org or contact our free helpline with any questions that you have at pcri.org/helpline. Our Federal Tax ID # is 95-4617875 and qualifies for maximum charitable gift deductions by individual donors.
The information on the Prostate Cancer Research Institute's KZitem channel is provided with the understanding that the Institute is not engaged in rendering medical advice or recommendation. The information provided in these videos should not replace consultations with qualified health care professionals to meet your individual medical needs.
#ProstateCancer #MarkScholzMD #PCRI
Негізгі бет Chemotherapy In
Пікірлер: 38